X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
XERAVA® (eravacycline) for injection is approved by the U.S. Food and Drug Administration (FDA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
La Jolla brings to Innoviva an established product portfolio, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections.
Lead Product(s): Angiotensin II
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Giapreza
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 22, 2022
Details:
Acquisition will strengthen Innoviva’s infectious disease portfolio with addition of GIAPREZA® (angiotensin II) and XERAVA® (eravacycline), and advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products.
Lead Product(s): Angiotensin II
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Giapreza
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 11, 2022
Details:
La Jolla will get double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories.
Lead Product(s): Angiotensin II
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Giapreza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: PAION UK LTD
Deal Size: $132.0 million Upfront Cash: $22.5 million
Deal Type: Licensing Agreement January 12, 2021
Details:
Combined company will offer two innovative therapies to treat patients suffering from life-threatening diseases.
Lead Product(s): Eravacycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Xerava
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Tetraphase Pharmaceuticals
Deal Size: $59.0 million Upfront Cash: $43.0 million
Deal Type: Acquisition June 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
